Acadian Asset Management LLC Has $6.05 Million Stake in IQVIA Holdings Inc. $IQV

Key Points

• Acadian Asset Management LLC has reduced its stake in IQVIA Holdings Inc. by 27.1%, owning 34,361 shares valued at approximately $6.05 million after selling 12,747 shares in the first quarter.
• Several institutional investors have increased their stakes, with notable boosts from Canada Pension Plan Investment Board (+7.3%) and JPMorgan Chase & Co. (+45.7%).
• Analyst ratings for IQVIA show strong support, with an average rating of "Moderate Buy" and a price target of $229.64, after various upgrades from firms like Evercore ISI and UBS Group.

Acadian Asset Management LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,361 shares of the medical research company's stock after selling 12,747 shares during the quarter. Acadian Asset Management LLC's holdings in IQVIA were worth $6,053,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Geneos Wealth Management Inc. raised its stake in shares of IQVIA by 3.0% during the first quarter. Geneos Wealth Management Inc. now owns 8,472 shares of the medical research company's stock valued at $1,494,000 after purchasing an additional 248 shares in the last quarter. Focus Partners Wealth raised its stake in shares of IQVIA by 10.1% during the first quarter. Focus Partners Wealth now owns 64,052 shares of the medical research company's stock valued at $11,293,000 after purchasing an additional 5,896 shares in the last quarter. Plato Investment Management Ltd raised its stake in shares of IQVIA by 17.0% during the first quarter. Plato Investment Management Ltd now owns 8,125 shares of the medical research company's stock valued at $1,448,000 after purchasing an additional 1,181 shares in the last quarter. Bayforest Capital Ltd bought a new stake in shares of IQVIA during the first quarter valued at about $203,000. Finally, SCS Capital Management LLC bought a new stake in shares of IQVIA during the first quarter valued at about $480,000. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on IQV. Robert W. Baird lifted their target price on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Truist Financial lifted their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $229.64.

IQVIA Trading Up 0.5%

IQV traded up $1.00 during trading on Tuesday, reaching $186.97. The company had a trading volume of 1,005,530 shares, compared to its average volume of 1,893,994. The firm's 50-day simple moving average is $182.87 and its 200 day simple moving average is $167.11. The company has a market cap of $31.78 billion, a price-to-earnings ratio of 27.06, a PEG ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $248.03. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter in the previous year, the business posted $2.64 EPS. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.